Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nocturne Acquisition Corporation (NASDAQ: MBTC, MBTCU, MBTCR) announced a definitive business combination with Cognos Therapeutics, a company focused on innovative medical devices for neurological diseases. The transaction values Cognos at approximately $120 million and involves an all-stock deal where Cognos shareholders will receive Nocturne common stock valued at $10.30 each. The proposed combination, expected to close in the second or third quarter of 2023, aims to enhance Cognos' access to capital for advancing its SINNAIS™ Implantable Smart Pump, designed to improve drug delivery for brain cancer treatment.
Nocturne Acquisition Corp. (NASDAQ: MBTCU) announced a $1,150,000 deposit into its trust account, allowing an extension for its initial business combination period from July 5, 2022 to October 5, 2022. This payment translates to $0.10 per public share and aims to facilitate future acquisitions in disruptive technologies, particularly in the blockchain and artificial intelligence sectors. The Company focuses on targets with an equity value between $300 million and $1 billion.
Nocturne Acquisition Corp. (NASDAQ:MBTCU) has deposited $1,150,000 in its trust account, equating to $0.10 per public share. This extension allows the company to extend the deadline for its initial business combination by three months, from April 5, 2022 to July 5, 2022. The company aims to pursue acquisitions in sectors focusing on disruptive technologies in blockchain and artificial intelligence, targeting equity values between $300 million and $1 billion.